Making and circumventing tolerance to cancer
- PMID: 19634191
- DOI: 10.1002/eji.200939612
Making and circumventing tolerance to cancer
Abstract
The interactions between cancer and immune cells are complex. Even though the mutations that cause cancer can create new antigens that are potentially "visible" to T cells, in most experimental model systems the growth of tumors is accompanied by induction of T-cell tolerance towards the tumor. How tolerance to tumors is induced and how tolerance can be broken by immunotherapy have been a main focus in cancer immunology. Here, we discuss experimental models used in cancer immunology. We argue that, while it is obviously easy for tumors to induce tolerance, it should be as easy to circumvent tolerance by the adoptive transfer of tumor-antigen-reactive T cells. Effective adoptive T-cell therapy has become feasible by methods to identify TCR against tumor-associated (self-) antigens with high affinity and to graft a new antigen specificity to patients' T cells by TCR gene transfer.
Similar articles
-
Generation of tumor-specific T-cell therapies.Blood Rev. 2006 Mar;20(2):61-9. doi: 10.1016/j.blre.2005.05.001. Epub 2005 Jun 22. Blood Rev. 2006. PMID: 15978709 Review.
-
Circumventing T-cell tolerance to tumour antigens.Biologicals. 2001 Sep-Dec;29(3-4):277-83. doi: 10.1006/biol.2001.0300. Biologicals. 2001. PMID: 11851328
-
Antigen choice in adoptive T-cell therapy of cancer.Curr Opin Immunol. 2009 Apr;21(2):190-9. doi: 10.1016/j.coi.2009.02.006. Epub 2009 Mar 16. Curr Opin Immunol. 2009. PMID: 19297140 Review.
-
Preclinical development of T cell receptor gene therapy.Curr Opin Immunol. 2009 Apr;21(2):209-14. doi: 10.1016/j.coi.2009.02.007. Epub 2009 Mar 25. Curr Opin Immunol. 2009. PMID: 19321326 Review.
-
Cancer immunogene therapy.Arch Immunol Ther Exp (Warsz). 2001;49(5):337-43. Arch Immunol Ther Exp (Warsz). 2001. PMID: 11798131 Review.
Cited by
-
Redirecting the immune response: role of adoptive T cell therapy.Hum Gene Ther. 2010 May;21(5):533-41. doi: 10.1089/hum.2010.033. Hum Gene Ther. 2010. PMID: 20201627 Free PMC article. Review.
-
A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.J Immunol. 2012 Dec 15;189(12):5622-31. doi: 10.4049/jimmunol.1200709. Epub 2012 Nov 9. J Immunol. 2012. PMID: 23144496 Free PMC article.
-
Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD(4+) T lymphocytes.Prion. 2010 Apr-Jun;4(2):66-71. doi: 10.4161/pri.4.2.12597. Epub 2010 Apr 4. Prion. 2010. PMID: 20622507 Free PMC article.
-
The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.PLoS One. 2013 Oct 23;8(10):e79082. doi: 10.1371/journal.pone.0079082. eCollection 2013. PLoS One. 2013. PMID: 24194959 Free PMC article.
-
MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.Cancer Immunol Immunother. 2013 Feb;62(2):359-69. doi: 10.1007/s00262-012-1336-z. Epub 2012 Aug 25. Cancer Immunol Immunother. 2013. PMID: 22926060 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources